Beyond gluten-free: a hopeful future for those who suffer from Celiac disease Gluten-free dietary products contain more sugar and fats but fewer nutrients and are generally more expensive. A gluten-free diet can […] February 14, 2024 · SciMingo
Looking forward: Azalea Vision's smart lens is a game-changer for ocular disorders January 24, 2024 · BioVox
V-Bio Ventures portfolio company Agomab raises $100 million Series C to advance fibrosis-focused pipeline — Round led by Fidelity Management & Research Company with participation from new investors EQT Life Sciences, Canaan and Dawn […] October 11, 2023 · V-Bio Ventures
V-Bio Ventures-funded Tanai Therapeutics develops first-in-class therapeutics for obesity Ghent, 6 December 2023 – VIB, Flanders’ leading life sciences institute, together with lead investor V-Bio Ventures has launched a […] December 6, 2023 · V-Bio Ventures
Fund+ Portfolio Company Tubulis Closes Upsized EUR 128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline Financing round co-led by EQT Life Sciences and Nextech Invest1, with participation from current and new leading global biotechnology investors […] March 14, 2024 · Press Release
miDiagnostics announces collaboration with Galapagos to develop closed-flow, ultra-rapid CAR-T sterility test for its point-of-care CAR-T manufacturing platform Leuven, Belgium, November 10, 2023 – miDiagnostics NV, a global technology leader in point-of-care diagnostics, today announced a collaboration agreement […] November 10, 2023 · Press Release
Azalea Vision Secures Prestigious European Innovation Council (EIC) Transition Grant Innovative Smart Contact Lens Developer Awarded €2.5M in Funding for Groundbreaking Ocular Health Technology Ghent, Belgium, March 12th, 2024 – […] March 12, 2024 · Press Release
Azalea Vision announces first on-eye test of ALMA, its revolutionary smart contact lens Promises New Hope for Patients with Vision Disorders Ghent, Belgium (December 4th, 2023) In a significant milestone, Azalea Vision, […] December 4, 2023 · Press Release
Obulytix is developing a revolutionary solution for antibiotic resistance Obulytix, a spin-off based on research results from Ghent University and KU Leuven, has built a platform that creates new ways to tackle bacterial infections. December 5, 2023 · Press Release
Pharmaceutical market access: how real-world data fuel better health beyond clinical trials Studies of a drug’s effectiveness and safety don’t end with clinical trials – they extend beyond market access when the […] September 27, 2023 · Janssen Pharmaceutica
V-Bio Ventures portfolio company Orionis Biosciences announces collaboration with Genentech to discover and develop molecular glue class medicines September 20, 2023, BOSTON, MA and GHENT, Belgium – Orionis Biosciences, a privately held life sciences company with an integrated […] September 20, 2023 · V-Bio Ventures
Augustine Therapeutics expands its leadership team and R&D platform, enters regulatory development. Leuven, Belgium, September 12th, 2023 – Augustine Therapeutics, a biotech company developing innovative therapies for neuromuscular and neurodegenerative disorders, announced […] September 12, 2023 · Press Release
V-Bio Ventures portfolio company Corteria Pharmaceuticals raises EUR 65 million to advance its transformational medicines for cardiovascular diseases Ghent, Belgium, 7 September 2023 – Corteria Pharmaceuticals, a V-Bio Ventures portfolio company, is a biopharmaceutical company specialized in the […] September 7, 2023 · V-Bio Ventures
The obesity revolution: will new drugs bring about big changes? The recent approval of the obesity and diabetes drugs Wegovy, Ozempic, and Mounjaro has brought about big headlines, but are […] June 21, 2023 · V-Bio Ventures
V-Bio Ventures portfolio company Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic Use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting TNFR2, as well as its […] May 15, 2023 · V-Bio Ventures